Similarly, the CFB antagonist iptacopan (LNP023) has demonstrated efficacy and good tolerability in an ongoing phase III trial for IgA nephropathy, suggesting promising application in breast cancer (30). Here, CFB is linked to IgA glomerulonephritis.